Medeiros, Mariana SilvaBotelho de Carvalho, Luís AndréAlves, MartaPapoila, AnaBaptista Carreira dos Santos, Hugo MiguelCapelo-Martínez, José LuisPinheiro, Luís Manuel Viegas de Campos2024-10-092024-10-092024-080301-1623PURE: 94071176PURE UUID: dbcbec7f-d56e-4cdc-8171-6f11ac369851Scopus: 85188991914WOS: 001191084300003PubMed: 38530585PubMedCentral: PMC11266244ORCID: /0000-0002-6032-8679/work/170346746http://hdl.handle.net/10362/173273Publisher Copyright: © The Author(s) 2024. Open access funding provided by FCT|FCCN (b-on).Purpose: T1 bladder cancer is known for its high progression and recurrence rates. Identifying aggressive tumours at the non-muscle-invasive stage is crucial to allow early interventions and subsequently increase patient survival. This study aimed to investigate the potential of the cubilin/myeloperoxidase (CUBN/MPO) ratio as a high-grade T1 bladder cancer biomarker. Methods: Urine samples were collected from 30 patients who underwent transurethral resection of the tumour with high-grade T1 bladder cancer (June 2015 to December 2019) before surgery. The urinary proteome was analysed using high-resolution mass spectrometry and the CUBN/MPO ratio was calculated. The primary outcome was the recurrence during the follow-up (around 31.5 months after resection). Univariate Cox regression and Kaplan–Meier curves were used for data analysis. Results: Patients with a low CUBN/MPO ratio exhibited upregulated MPO and/or downregulated CUBN. This group of patients had a higher incidence of disease recurrence and progression. Low CUBN/MPO ratio was significantly associated with a higher likelihood of recurrence, progression, and death. It is worth noting that this study was exploratory and conducted on a small sample size, so further research is needed to validate these findings in larger cohorts. Conclusion: This study highlights the potential of the CUBN/MPO ratio as a prognostic biomarker for high-grade T1 bladder cancer.111037765engCUBN/MPONon-muscle-invasive bladder cancerRecurrenceUrinary proteomeNephrologyUrologySDG 3 - Good Health and Well-beingjournal article10.1007/s11255-024-03971-4https://www.scopus.com/pages/publications/85188991914